ClinicalTrials.gg
CompletedNCT06237049Updated Sep 30, 2025Results posted

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

A Phase 2 interventional study of BNT162b2 (Omi XBB.1.5)/RIV and BNT162b2 (Omi XBB.1.5) in Influenza, Human, SARS-CoV-2 Infection and COVID-19, sponsored by Pfizer. Completed at 30 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
644
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Influenza, Human by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Pfizer.

Enrollment
8th of 11
644 · median 882
Started
2024
with 2 others
Phase 2
3 of 15
1 open now
Registered
13th of 15
by date

Among the 15 studies in Influenza, Human by Pfizer, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 2, and was the 13th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

1 of the 15 studies in Influenza, Human by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.

Read the detailed description

This is a Phase 1/2 study to evaluate the safety, tolerability, and immunogenicity of licensed BNT162b2 (Omi XBB.1.5) and recombinant influenza vaccine (RIV) administered together as a single injection (referred to as BNT162b2 [Omi XBB.1.5]/RIV) in healthy adults 50 years of age or older.

The safety, tolerability, and immunogenicity of BNT162b2 (OmiXBB1.5)/RIV administered as a single injection will be compared to BNT162b2 (Omi XBB.1.5) and RIV administered simultaneously as 2 separate injections (coadministered), and to BNT162b2 (Omi XBB.1.5) or RIV when administered alone.

Across Phases 1 and 2, approximately 640 participants in total will be randomized with an equal randomization ratio to 1 of 4 vaccine groups and stratified by age.

03

Conditions studied

  • Influenza, Human
  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • Grippe
  • Flu
  • Influenza Vaccine
  • RNA Vaccine
  • COVID-19
  • Coronavirus Vaccine
  • SARS-CoV-2
  • mRNA Vaccine
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 50 years or older at Visit 1 (Day 1).
  • Participants who are willing and able to comply with all scheduled visits, the plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving signed as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Known infection with (HIV), virus (HCV), or virus (HBV).
  • History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study interventions.
  • Participants with a history of disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, temporal arteritis, psoriasis, and/or insulin-dependent diabetes mellitus.
  • individuals with known or suspected immunodeficiency, determined by history and/or laboratory/physical examination.
  • Current heart disease, uncontrolled hypertension, or a prior history of myocarditis or pericarditis.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant, plan to become pregnant during the study, or are breastfeeding.
  • Prior history of ischemic stroke or .
  • Prior history of Guillain-Barré syndrome (GBS).
  • Participants with a calculated of ≥35.
  • Receipt of chronic medications with known systemic immunosuppressant effects (including cytotoxic agents or systemic ), or radiotherapy, within 60 days before enrollment through conclusion of the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies used for the treatment or prevention of COVID 19 or those that are considered immunosuppressive, from 90 days before study intervention administration, or planned receipt throughout the study.
  • Vaccination with any or licensed influenza vaccine within 6 months (180 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza.
  • Vaccination with any investigational or licensed COVID-19 vaccine within 6 months (180 days) before study intervention administration.
  • Participation in other studies involving administration of an investigational product within 28 days prior to, and/or during, participation in this study.
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction that in the opinion of the investigator might interfere with the study conduct or completion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
644 participants (actual)

Study arms

  • Experimental
    BNT162b2 (Omi XBB.1.5)/RIV and placebo

    Participants will receive a single injection combination of BNT162b2 (Omi XBB.1.5) and RIV and normal saline placebo

    Biological: BNT162b2 (Omi XBB.1.5)/RIV · Other: Normal saline placebo

  • Experimental
    BNT162b2 (Omi XBB.1.5) and RIV

    Participants will receive BNT162b2 (Omi XBB.1.5) and RIV

    Biological: BNT162b2 (Omi XBB.1.5) · Biological: RIV

  • Active comparator
    BNT162b2 (Omi XBB.1.5) and placebo

    Participants will receive BNT162b2 (Omi XBB.1.5) and normal saline placebo

    Biological: BNT162b2 (Omi XBB.1.5) · Other: Normal saline placebo

  • Active comparator
    RIV and placebo

    Participants will receive RIV and normal saline placebo

    Biological: RIV · Other: Normal saline placebo

Interventions

  • BiologicalBNT162b2 (Omi XBB.1.5)/RIV

    Drug page: BNT162 Vaccine

    Combination of BNT162b2 (Omi XBB.1.5) and RIV

  • Licensed COVID-19 vaccine

  • BiologicalRIV

    Licensed recombinant influenza vaccine

  • OtherNormal saline placebo

    Normal saline (solution for injection)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination

    Local reactions included redness, swelling and pain at injection site, recorded by participants in an electronic diary (e-diary). Severity of all local reactions were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure local reactions with any severity were reported for each left arm's deltoid and right arm's deltoid of each vaccine Group 1, 2, 3 and 4.

    Time frame: Day 1 to Day 7 following Vaccination on Day 1

  2. Percentage of Participants Who Reported Any Systemic Events up to 7 Days Following Vaccination

    Systemic events: fever, fatigue, headache, vomiting, diarrhea, chills, new/worsened muscle pain, new/worsened joint pain were recorded by participants in e-diary. Severity of all systemic events were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure systemic events with any severity were reported.

    Time frame: Day 1 to Day 7 following Vaccination on Day 1

  3. Percentage of Participants Who Reported Any Adverse Events (AEs) From Vaccination Through 4 Weeks After Vaccination

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events collected by systematic assessment (local reactions and systemic events) were excluded from evaluation.

    Time frame: From Vaccination on Day 1 through 4 weeks after Vaccination

  4. Percentage of Participants Who Reported Any Serious Adverse Events (SAEs) From Vaccination Through 6 Months After Vaccination

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other important medical events per protocol of the study. Events collected by systematic assessment (local reactions and systemic events) were excluded from evaluation.

    Time frame: From Vaccination on Day 1 through 6 months after Vaccination

  5. Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron (XBB.1.5)-Neutralizing Titers Before Vaccination

    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.

    Time frame: Before Vaccination on Day 1

  6. GMTs of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers at 4 Weeks After Vaccination

    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.

    Time frame: At 4 weeks after Vaccination on Day 1

  7. Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers From Before Vaccination to 4 Weeks After Vaccination

    GMFR was the ratio of the geometric mean titre values 4 weeks after vaccination to before vaccination. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.

    Time frame: From before Vaccination on Day 1 to 4 weeks after Vaccination

  8. Percentages of Participants With Seroresponse to SARS-CoV-2 Omicron (XBB.1.5) at 4 Weeks After Vaccination

    Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination measure of \>=4\*LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method. As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.

    Time frame: At 4 weeks after Vaccination on Day 1

  9. GMTs of Strain Specific Hemagglutinin Inhibition Assay (HAI) Titers Before Vaccination

    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMTs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

    Time frame: Before Vaccination on Day 1

  10. GMTs of Strain Specific Hemagglutinin Inhibition Assay (HAI) Titers at 4 Weeks After Vaccination

    GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMTs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

    Time frame: At 4 weeks after Vaccination on Day 1

  11. GMFR of Strain Specific HAI Titers From Before Vaccination to 4 Weeks After Vaccination

    GMFR was the ratio of the geometric mean titre values 4 weeks after vaccination to before vaccination. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMFRs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

    Time frame: From before Vaccination to 4 weeks after Vaccination on Day 1

  12. Percentages of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination

    Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a minimum 4-fold rise at the time point of interest. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated seroconversion of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

    Time frame: At 4 weeks after Vaccination on Day 1

  13. Percentages of Participants With HAI Titers >= 1:40 Before Vaccination

    Percentages of participants with HAI titers \>= 1:40 before vaccination along with the associated 2-sided 95% CIs, was provided for each vaccine group in this outcome measure. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

    Time frame: Before Vaccination on Day 1

  14. Percentages of Participants With HAI Titers >= 1:40 at 4 Weeks After Vaccination

    Percentages of participants with HAI titers \>= 1:40 at 4 weeks after vaccination along with the associated 2-sided 95% CIs, was provided for each vaccine group in this outcome measure. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As outcome measure evaluated of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

    Time frame: At 4 Weeks after Vaccination on Day 1

07

Results

Posted Sep 30, 2025

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + Placebo
Started160163160161
Vaccinated160161160160
Completed145155151151
Not completed158910
Withdrew: Death0001
Withdrew: Lost to follow-up11588
Withdrew: Protocol violation0101
Withdrew: Withdrawal by subject4210

Outcome measures

PrimaryPercentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination

Local reactions included redness, swelling and pain at injection site, recorded by participants in an electronic diary (e-diary). Severity of all local reactions were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure local reactions with any severity were reported for each left arm's deltoid and right arm's deltoid of each vaccine Group 1, 2, 3 and 4.

Time frame:
Day 1 to Day 7 following Vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination
Percentage of participantsGroup 1, BNT162b2/RIV + Placebo: BNT162b2/RIVGroup 1, BNT162b2/RIV + Placebo: PlaceboGroup 2, BNT162b2 + RIV: BNT162b2Group 2, BNT162b2 + RIV: RIVGroup 3, BNT162b2 + Placebo: BNT162b2Group 3, BNT162b2 + Placebo: PlaceboGroup 4, RIV + Placebo: RIVGroup 4, RIV + Placebo: Placebo
Pain at injection site56.3 (48.2 to 64.1)11.9 (7.3 to 17.9)59.0 (51.0 to 66.7)38.5 (31.0 to 46.5)62.5 (54.5 to 70.0)9.4 (5.3 to 15.0)36.9 (29.4 to 44.9)8.1 (4.4 to 13.5)
Redness8.8 (4.9 to 14.2)1.3 (0.2 to 4.4)5.0 (2.2 to 9.6)3.1 (1.0 to 7.1)5.0 (2.2 to 9.6)0.6 (0.0 to 3.4)6.3 (3.0 to 11.2)0.6 (0.0 to 3.4)
Swelling9.4 (5.3 to 15.0)1.3 (0.2 to 4.4)6.2 (3.0 to 11.1)3.1 (1.0 to 7.1)5.6 (2.6 to 10.4)0.6 (0.0 to 3.4)5.0 (2.2 to 9.6)0.6 (0.0 to 3.4)
PrimaryPercentage of Participants Who Reported Any Systemic Events up to 7 Days Following Vaccination

Systemic events: fever, fatigue, headache, vomiting, diarrhea, chills, new/worsened muscle pain, new/worsened joint pain were recorded by participants in e-diary. Severity of all systemic events were evaluated as mild, moderate, severe or potentially life-threatening. In this outcome measure systemic events with any severity were reported.

Time frame:
Day 1 to Day 7 following Vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reported Any Systemic Events up to 7 Days Following Vaccination
Percentage of participantsGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + Placebo
Fever1.9 (0.4 to 5.4)6.2 (3.0 to 11.1)6.3 (3.0 to 11.2)0 (0.0 to 2.3)
Fatigue36.3 (28.8 to 44.2)39.1 (31.5 to 47.1)40.6 (32.9 to 48.7)33.1 (25.9 to 41.0)
Headache24.4 (17.9 to 31.8)31.1 (24.0 to 38.8)26.9 (20.2 to 34.4)16.9 (11.4 to 23.6)
Vomiting0 (0.0 to 2.3)3.1 (1.0 to 7.1)1.9 (0.4 to 5.4)0 (0.0 to 2.3)
Diarrhea8.1 (4.4 to 13.5)11.2 (6.8 to 17.1)11.3 (6.8 to 17.2)7.5 (3.9 to 12.7)
Chills8.8 (4.9 to 14.2)14.9 (9.8 to 21.4)15.0 (9.9 to 21.5)6.9 (3.5 to 12.0)
New or worsened muscle pain13.1 (8.3 to 19.4)22.4 (16.2 to 29.6)15.0 (9.9 to 21.5)8.1 (4.4 to 13.5)
New or worsened joint pain7.5 (3.9 to 12.7)13.7 (8.8 to 20.0)10.0 (5.8 to 15.7)4.4 (1.8 to 8.8)
PrimaryPercentage of Participants Who Reported Any Adverse Events (AEs) From Vaccination Through 4 Weeks After Vaccination

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events collected by systematic assessment (local reactions and systemic events) were excluded from evaluation.

Time frame:
From Vaccination on Day 1 through 4 weeks after Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reported Any Adverse Events (AEs) From Vaccination Through 4 Weeks After Vaccination
Percentage of participantsGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + Placebo
Percentage of Participants Who Reported Any Adverse Events (AEs) From Vaccination Through 4 Weeks After Vaccination4.4 (1.8 to 8.8)3.7 (1.4 to 7.9)5.6 (2.6 to 10.4)5.6 (2.6 to 10.4)
PrimaryPercentage of Participants Who Reported Any Serious Adverse Events (SAEs) From Vaccination Through 6 Months After Vaccination

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other important medical events per protocol of the study. Events collected by systematic assessment (local reactions and systemic events) were excluded from evaluation.

Time frame:
From Vaccination on Day 1 through 6 months after Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reported Any Serious Adverse Events (SAEs) From Vaccination Through 6 Months After Vaccination
Percentage of participantsGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + Placebo
Percentage of Participants Who Reported Any Serious Adverse Events (SAEs) From Vaccination Through 6 Months After Vaccination1.9 (0.4 to 5.4)0.6 (0.0 to 3.4)0 (0.0 to 2.3)1.9 (0.4 to 5.4)
PrimaryGeometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron (XBB.1.5)-Neutralizing Titers Before Vaccination

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.

Time frame:
Before Vaccination on Day 1
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron (XBB.1.5)-Neutralizing Titers Before Vaccination
TiterGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + Placebo
Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron (XBB.1.5)-Neutralizing Titers Before Vaccination311.2 (236.2 to 409.9)285.4 (220.4 to 369.5)338.5 (256.9 to 446.0)
PrimaryGMTs of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers at 4 Weeks After Vaccination

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.

Time frame:
At 4 weeks after Vaccination on Day 1
Reported as:
Geometric mean · Titer
GMTs of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers at 4 Weeks After Vaccination
TiterGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + Placebo
GMTs of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers at 4 Weeks After Vaccination2162.4 (1719.6 to 2719.4)2581.3 (2076.2 to 3209.5)3644.7 (2853.7 to 4654.8)
PrimaryGeometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers From Before Vaccination to 4 Weeks After Vaccination

GMFR was the ratio of the geometric mean titre values 4 weeks after vaccination to before vaccination. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.

Time frame:
From before Vaccination on Day 1 to 4 weeks after Vaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers From Before Vaccination to 4 Weeks After Vaccination
RatioGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + Placebo
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron (XBB.1.5)-Neutralizing Titers From Before Vaccination to 4 Weeks After Vaccination6.1 (4.7 to 7.9)8.0 (6.3 to 10.1)9.4 (7.2 to 12.3)
PrimaryPercentages of Participants With Seroresponse to SARS-CoV-2 Omicron (XBB.1.5) at 4 Weeks After Vaccination

Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination measure of \>=4\*LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method. As planned, outcome measure evaluated GMTs of SARS-CoV-2 Omicron (XBB.1.5), hence results are reported only for those reporting groups where BNT162b2 (Omi XBB.1.5) was administered. Data was not collected and not reported for reporting group "Group 4: RIV + Placebo", where BNT162b2 (Omi XBB.1.5) was not administered.

Time frame:
At 4 weeks after Vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentages of Participants With Seroresponse to SARS-CoV-2 Omicron (XBB.1.5) at 4 Weeks After Vaccination
Percentage of participantsGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + Placebo
Percentages of Participants With Seroresponse to SARS-CoV-2 Omicron (XBB.1.5) at 4 Weeks After Vaccination53.7 (45.3 to 61.9)60.5 (52.4 to 68.2)63.8 (55.6 to 71.4)
PrimaryGMTs of Strain Specific Hemagglutinin Inhibition Assay (HAI) Titers Before Vaccination

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMTs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

Time frame:
Before Vaccination on Day 1
Reported as:
Geometric mean · Titer
GMTs of Strain Specific Hemagglutinin Inhibition Assay (HAI) Titers Before Vaccination
TiterGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 4: RIV + Placebo
A/Victoria/4897/ 2022 (H1N1) HAI43.8 (33.9 to 56.5)60.7 (47.7 to 77.1)62.6 (49.0 to 79.8)
A/Darwin/9/ 2021 (H3N2) HAI34.8 (26.8 to 45.1)42.3 (32.7 to 54.9)44.3 (33.8 to 58.1)
B/Michigan/1/ 2021 HAI105.9 (82.4 to 136.2)101.8 (81.4 to 127.4)114.9 (92.0 to 143.6)
B/Phuket/3073/ 2013 HAI186.6 (151.8 to 229.5)218.5 (181.3 to 263.2)228.8 (185.9 to 281.7)
PrimaryGMTs of Strain Specific Hemagglutinin Inhibition Assay (HAI) Titers at 4 Weeks After Vaccination

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMTs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

Time frame:
At 4 weeks after Vaccination on Day 1
Reported as:
Geometric mean · Titer
GMTs of Strain Specific Hemagglutinin Inhibition Assay (HAI) Titers at 4 Weeks After Vaccination
TiterGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 4: RIV + Placebo
A/Victoria/4897/ 2022 (H1N1) HAI324.4 (250.4 to 420.2)374.7 (299.4 to 469.1)389.6 (309.4 to 490.5)
A/Darwin/9/ 2021 (H3N2) HAI397.7 (310.4 to 509.7)489.7 (393.9 to 608.9)557.2 (440.8 to 704.2)
B/Michigan/1/ 2021 HAI464.0 (384.5 to 559.9)427.5 (360.0 to 507.6)496.0 (408.6 to 602.1)
B/Phuket/3073/ 2013 HAI669.7 (568.4 to 789.0)769.5 (658.9 to 898.7)775.7 (656.1 to 917.1)
PrimaryGMFR of Strain Specific HAI Titers From Before Vaccination to 4 Weeks After Vaccination

GMFR was the ratio of the geometric mean titre values 4 weeks after vaccination to before vaccination. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated GMFRs of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

Time frame:
From before Vaccination to 4 weeks after Vaccination on Day 1
Reported as:
Geometric mean · Ratio
GMFR of Strain Specific HAI Titers From Before Vaccination to 4 Weeks After Vaccination
RatioGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 4: RIV + Placebo
A/Victoria/4897/ 2022 (H1N1) HAI6.6 (5.2 to 8.5)5.7 (4.5 to 7.2)5.7 (4.5 to 7.2)
A/Darwin/9/ 2021 (H3N2) HAI9.9 (7.7 to 12.6)10.1 (8.0 to 12.8)11.0 (8.5 to 14.3)
B/Michigan/1/ 2021 HAI4.3 (3.5 to 5.3)4.1 (3.4 to 5.0)4.2 (3.3 to 5.4)
B/Phuket/3073/ 2013 HAI3.6 (2.9 to 4.4)3.5 (2.9 to 4.2)3.4 (2.8 to 4.1)
PrimaryPercentages of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination

Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a minimum 4-fold rise at the time point of interest. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated seroconversion of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

Time frame:
At 4 weeks after Vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentages of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination
Percentage of participantsGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 4: RIV + Placebo
A/Victoria/4897/ 2022 (H1N1) HAI62.7 (54.6 to 70.4)67.7 (59.8 to 74.9)61.3 (53.1 to 69.0)
A/Darwin/9/2021 (H3N2)76.5 (68.9 to 82.9)79.1 (71.9 to 85.2)76.1 (68.6 to 82.6)
B/Michigan/1/202154.9 (46.7 to 62.9)53.2 (45.1 to 61.1)51.0 (42.8 to 59.1)
B/Phuket/3073/201349.7 (41.5 to 57.9)53.8 (45.7 to 61.8)46.5 (38.4 to 54.6)
PrimaryPercentages of Participants With HAI Titers >= 1:40 Before Vaccination

Percentages of participants with HAI titers \>= 1:40 before vaccination along with the associated 2-sided 95% CIs, was provided for each vaccine group in this outcome measure. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As planned, outcome measure evaluated of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

Time frame:
Before Vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentages of Participants With HAI Titers >= 1:40 Before Vaccination
Percentage of participantsGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 4: RIV + Placebo
A/Victoria/4897/ 2022 (H1N1) HAI55.6 (47.3 to 63.6)69.6 (61.8 to 76.7)70.3 (62.5 to 77.4)
A/Darwin/9/2021 (H3N2)49.7 (41.5 to 57.9)57.6 (49.5 to 65.4)54.8 (46.7 to 62.8)
B/Michigan/1/202174.5 (66.8 to 81.2)81.6 (74.7 to 87.3)81.3 (74.2 to 87.1)
B/Phuket/3073/201389.5 (83.6 to 93.9)94.3 (89.5 to 97.4)93.5 (88.5 to 96.9)
PrimaryPercentages of Participants With HAI Titers >= 1:40 at 4 Weeks After Vaccination

Percentages of participants with HAI titers \>= 1:40 at 4 weeks after vaccination along with the associated 2-sided 95% CIs, was provided for each vaccine group in this outcome measure. Exact 2-sided CI, based on the Clopper and Pearson method. The 4 virus strains which were evaluated and reported in this outcome measure were A/Victoria/4897/2022 (H1N1) HAI, A/Darwin/9/2021 (H3N2) HAI, B/Michigan/1/2021 HAI and B/Phuket/3073/2013 HAI. As outcome measure evaluated of strain specific HAI, hence results are reported only for those reporting groups where RIV was administered. Data was not collected and not reported for reporting group "Group 3: BNT162b2 (Omi XBB.1.5) + Placebo", where RIV was not administered.

Time frame:
At 4 Weeks after Vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentages of Participants With HAI Titers >= 1:40 at 4 Weeks After Vaccination
Percentage of participantsGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 4: RIV + Placebo
A/Victoria/4897/ 2022 (H1N1) HAI90.8 (85.1 to 94.9)95.6 (91.1 to 98.2)96.8 (92.6 to 98.9)
A/Darwin/9/2021 (H3N2)95.4 (90.8 to 98.1)97.5 (93.6 to 99.3)96.1 (91.8 to 98.6)
B/Michigan/1/202198.0 (94.4 to 99.6)100.0 (97.7 to 100.0)99.4 (96.5 to 100.0)
B/Phuket/3073/201399.3 (96.4 to 100.0)100.0 (97.7 to 100.0)100.0 (97.6 to 100.0)

Adverse events

Collected over AEs by systematic assessment: Day 1 up to 7 Days following Vaccination; AEs by Non-systematic assessment: a) Serious AEs- Day 1 of Vaccination up to 6 months of follow-up after Vaccination, b) Other AEs- Day 1 of Vaccination up to 4 weeks of follow-up after Vaccination; All-cause mortality: Day 1 of Vaccination up to 6 months of follow-up after Vaccination. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + Placebo0/160 (0%)3/160 (1.9%)114/160 (71.3%)
Group 2: BNT162b2 (Omi XBB.1.5) + RIV0/161 (0%)1/161 (0.6%)117/161 (72.7%)
Group 3: BNT162b2 (Omi XBB.1.5) + Placebo0/160 (0%)0/160 (0%)115/160 (71.9%)
Group 4: RIV + Placebo1/160 (0.6%)3/160 (1.9%)88/160 (55%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + Placebo
DeathGeneral disorders0/1600/1610/1601/160
AppendicitisInfections and infestations1/1600/1610/1600/160
Infected skin ulcerInfections and infestations1/1600/1610/1600/160
Localised infectionInfections and infestations0/1600/1610/1601/160
Urinary tract infectionInfections and infestations0/1600/1610/1601/160
Metastatic squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1600/1610/1601/160
Transient ischaemic attackNervous system disorders1/1600/1610/1600/160
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1600/1610/1601/160
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1600/1610/1601/160
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1600/1610/1601/160
Most frequent other events
Showing 10 of 53
Most frequent other events
EventGroup 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + Placebo
Injection site pain (PAIN AT THE INJECTION SITE) left deltoidGeneral disorders90/16095/161100/16059/160
Fatigue (FATIGUE)General disorders58/16063/16165/16053/160
Injection site pain (PAIN AT THE INJECTION SITE) right deltoidGeneral disorders19/16062/16115/16013/160
Headache (HEADACHE)Nervous system disorders39/16050/16143/16027/160
Myalgia (NEW OR WORSENED MUSCLE PAIN)Musculoskeletal and connective tissue disorders21/16036/16124/16013/160
Chills (CHILLS)General disorders14/16024/16124/16011/160
Arthralgia (NEW OR WORSENED JOINT PAIN)Musculoskeletal and connective tissue disorders12/16022/16116/1607/160
Diarrhoea (DIARRHEA)Gastrointestinal disorders13/16018/16118/16012/160
Injection site swelling (SWELLING) left deltoidGeneral disorders15/16010/1619/1608/160
Injection site erythema (REDNESS) left deltoidGeneral disorders14/1608/1618/16010/160

Baseline characteristics

Safety analysis set (SAS) consisted of all participants who received at least 1 dose of the study intervention.

Age, Continuous
Age, Continuous(Years)Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + PlaceboTotal
Mean63.9 ± 8.4063.9 ± 9.0662.9 ± 7.7363.9 ± 7.6663.7 ± 8.22
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + PlaceboTotal
Female879210083362
Male73696077279
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + PlaceboTotal
Hispanic or Latino28282921106
Not Hispanic or Latino132133131137533
Unknown or Not Reported00022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: BNT162b2 (Omi XBB.1.5)/ RIV + PlaceboGroup 2: BNT162b2 (Omi XBB.1.5) + RIVGroup 3: BNT162b2 (Omi XBB.1.5) + PlaceboGroup 4: RIV + PlaceboTotal
American Indian or Alaska Native02114
Asian563620
Native Hawaiian or Other Pacific Islander02024
Black or African American37383030135
White117111124117469
More than one race02226
Unknown or Not Reported10023
08

Study locations

30 sites
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • GW Medical Faculty Associates
    Washington D.C., District of Columbia 20037, United States
  • GW Vaccine Research Unit
    Washington D.C., District of Columbia 20037, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Optimal Research
    Melbourne, Florida 32934, United States
  • Headlands Research Orlando
    Orlando, Florida 32819, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Winter Park, Florida 32789, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Optimal Research
    Peoria, Illinois 61614, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
    Springfield, Missouri 65802, United States
  • Bio-Kinetic Clinical Applications, LLD dba QPS-MO
    Springfield, Missouri 65802, United States
  • Bio-Kinetic Clinical Applications LLC DBA QPS-MO(Patient Screening Center)
    Springfield, Missouri 65807, United States
  • Las Vegas Clinical Trials
    Las Vegas, Nevada 89030, United States
  • Las Vegas Clinical Trials
    North Las Vegas, Nevada 89030, United States
  • ActivMed Practices & Research, LLC.
    Portsmouth, New Hampshire 03801, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Centricity Research Columbus Ohio Multispecialty
    Columbus, Ohio 43213, United States
  • Clinical Research Associates Inc
    Nashville, Tennessee 37203, United States
  • DM Clinical Research- Cyfair
    Houston, Texas 77065, United States
  • DM Clinical Research - Bellaire
    Houston, Texas 77081, United States
  • SMS Clinical Research
    Mesquite, Texas 75149, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • IMA Clinical Research San Antonio
    San Antonio, Texas 78229, United States
  • DM Clinical Research - MDC
    Tomball, Texas 77375, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Sep 2024, 7 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 7 months is close to that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 1, 2024
StartActual
Jan 31, 2024
Primary completionActual
Sep 13, 2024
CompletionActual
Sep 13, 2024
Results first posted
Sep 30, 2025
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06237049
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Jan 31, 2024
Primary completion
Sep 13, 2024
Completion
Sep 13, 2024
Results posted
Sep 30, 2025
Last update
Sep 30, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion